Cross border venture financing in the medical devices sector slowed in the final quarter of 2020.

Deals worth $1.25 billion were announced during the three-month period ending Dec. 31, a 6 percent decrease from the third quarter and a 0.8 percent dropoff compared with Q4 2019. The value, however, jumped 56.4 percent compared with the fourth quarter of 2019. The financing was led by Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings, and T. Rowe Price Associates’ $200 million venture financing of Tempus Labs, according to GlobalData’s deals database.
 
Comparing cross border deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $823.59 million. At the country level, the United States topped the list in terms of deal value at $811.3 million.
 
North America was the top region for medical devices industry cross border venture financing deals globally, followed by Europe and then Middle East and Africa.
 
The top country in terms of cross border venture financing deals activity in Q4 2020 was the United States with 24 deals, followed by the Israel with six and Switzerland with five.
 
The top five cross border venture financing deals in medical devices industry accounted for 48.4 percent of the overall value during Q4 2020. The combined value of the top five cross border venture financing deals stood at $605 million, against the overall value of $1.25 billion recorded for the quarter.
 
The top five medical devices industry cross border venture financing deals of Q4 2020 tracked by GlobalData were:

• Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings and T. Rowe Price Associates’ $200 million venture financing of Tempus Labs
• The $150 million venture financing of Singlera Genomics by CICC Kai Tak Fund, DETONG Capital Partners, FutureX Skyline Capital, Huamei International, Linden Asset Management, Prosperico Ventures, Proxima Ventures, Shanghai Free Trade Zone Fund Tao Capital, Shanghai Furong Investment, Shenzhen Green Pine Capital Partners and Wuxi Financial Investment
• ACE &SA, Alychlo, aMoon Partners, Credit Suisse Group, Endeavour Vision, Eurazeo Growth, Famille C Invest, Generation Investment Management, Hitachi Ventures, Pictet & Cie Group and Swisscom Ventures’ $110 million venture financing of Sophia Genetics
• The $80 million venture financing of Pear Therapeutics by 5AM Venture Management, Arboretum Ventures, CrimsoNox Capital, EDBI, Forth Management, Jazz Venture Partners, Novartis, Pilot House Ventures Group, Quad Investment Management, Sarissa Capital Management, Shanda Group, SoftBank Vision Fund II and Temasek Holdings (Private)
• Bold Capital Partners, Khosla Ventures, Omron Healthcare, Qualcomm Ventures and WP Global Partner’ venture financing of AliveCor for $65 million.